Table 1.

Clinical characteristics of the studied patient cohort.

Clinical Characteristics	Categories
Age (yr)	Mean: 59.0; <50: 28 (19.4%); ≥50: 116 (80.6%)
T category	pT1a: 9 (6.3%); pT1b: 37 (25.7%); pT1c: 82 (56.9%); pT1mic: 6 (4.2%); pT2: 10 (6.9%)
N category	N0: 141 (97.9%); N1: 3 (2.1%)
Stage	UICC I: 132 (91.7%); UICC II: 12 (8.3%)
Tumor size (mm)	<10: 38 (26.4%); 10–20: 96 (66.7%); >20: 10 (6.9%)
Histological grading	G1: 37 (25.7%); G2: 100 (69.4%); G3: 4 (2.8%); n.a. 3 (2.1%)
Histological typing	lobular: 22 (15.3%); no special type: 100 (69.4%); other: 22 (15.3%)
Ki67 (%)	<20: 109 (75.7%); ≥20: 31 (21.5%); n.a.: 4 (2.8%)
ER status	positive: 139 (96.5%); negative: 1 (0.7%); n.a.: 4 (2.8%)
PR status	positive: 130 (90.3%); negative: 11 (7.6%); n.a.: 3 (2.1%)
Her2 status	positive: 7 (4.9%); negative: 132 (91.7%); n.a.: 5 (3.5%)
Subtype	Luminal A: 96 (66.7%); Luminal B: 43 (29.9%); n.a.: 5 (3.5%)
Hormone therapy	Yes: 130 (90.3%); No: 14 (9.7%)
Chemotherapy	Yes: 10 (6.9%); No: 134 (93.1%)